Long-Term Disability Risk Seen After Childhood Bacterial Meningitis
26 Jan 2024
Clinical Result
FRIDAY, Jan. 26, 2024 -- Childhood bacterial meningitis significantly increases the risk for having at least one of seven long-term disabilities, according to a study published online Jan. 19 in JAMA Network Open.
Salini Mohanty, Dr.P.H., from Merck & Co. Inc. in Rahway, New Jersey, and colleagues assessed the long-term risk for disabilities among individuals diagnosed with bacterial meningitis in childhood. The analysis included 36,230 Swedish individuals diagnosed with bacterial meningitis (younger than 18 years) and matched (1:9) general population controls with up to 35 years of follow-up (1987 through 2021).
The researchers found that individuals diagnosed with bacterial meningitis had a higher cumulative incidence of all seven examined disabilities (cognitive disabilities, seizures, hearing loss, motor function disorders, visual disturbances, behavioral and emotional disorders, and intracranial structural injuries), with 29.0 percent having at least one disability. The highest relative risk for cases versus controls was seen for intracranial structural injuries (hazard ratio, 26.04), hearing loss (hazard ratio, 7.90), and motor function disorders (hazard ratio, 4.65). Risks for cognitive disabilities, seizures, hearing loss, and motor function disorders were significantly higher for Streptococcus pneumoniae infection versus Haemophilus influenzae infection or Neisseria meningitidis infection. Risk for cognitive disabilities, seizures, behavioral and emotional disorders, and intracranial structural injuries were significantly higher for children diagnosed with bacterial meningitis younger than the median age (1.5 years at diagnosis).
"The relative risk of disabilities tended to be highest during the first years after a diagnosis of bacterial meningitis but remained higher during the period starting over five years after diagnosis, suggesting that bacterial meningitis has both acute and long-term consequences," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.